Astegolimab Lowers Exacerbation Rates Across COPD Phenotypes

ReachMD Healthcare Image

For patients with COPD who continue to experience frequent exacerbations despite optimized inhaled therapy, biologic treatment options have largely focused on eosinophilic inflammation. But could targeting a broader inflammatory pathway extend therapeutic benefit beyond eosinophil-defined populations?

A prespecified pooled analysis of the ALIENTO and ARNASA trials, published in the American Journal of Respiratory and Critical Care Medicine, suggests that astegolimab, an antibody targeting the interleukin-33 (IL-33) receptor ST2, may reduce exacerbation frequency across a clinically heterogeneous COPD population.

Targeting Inflammation Beyond Eosinophils
IL-33 is an epithelial-derived alarmin released in response to environmental and infectious triggers. Through its ST2 receptor, it activates downstream pathways involved in both eosinophilic and neutrophilic inflammation. Astegolimab blocks this signaling pathway, offering a potential approach to exacerbation prevention that does not depend exclusively on elevated blood eosinophil counts.

The pooled analysis combined 2 randomized, double-blind, placebo-controlled trials: phase 2b ALIENTO and phase 3 ARNASA. Together, they randomized 2,682 participants across 39 countries, regardless of baseline eosinophil count, chronic bronchitis status, or current versus former smoking status. Participants had a history of at least 2 moderate or severe exacerbations and received astegolimab 476 mg every 2 weeks, every 4 weeks, or placebo for 52 weeks alongside optimized maintenance therapy.

Most participants were already receiving intensive treatment: 76.8% used triple inhaled therapy, and 87.2% had blood eosinophil counts below 300 cells/μL.

Modest but Consistent Reduction in Exacerbations
Astegolimab given every 2 weeks reduced the annualized rate of moderate or severe COPD exacerbations by 15% compared with placebo (rate ratio [RR], 0.85; 95% CI, 0.76–0.96; p=0.0077). Adjusted annualized rates were 1.04 versus 1.22 events per patient-year, an absolute difference of 0.18 exacerbations annually.

The every-4-week regimen also reduced exacerbations, although slightly less effectively, with a 12% relative reduction (RR, 0.88; 95% CI, 0.78–0.99; p=0.0265). Importantly, the treatment effect was directionally consistent across the individual trials, although only ALIENTO independently achieved statistical significance for the every-2-week regimen.

The signal extended to severe exacerbations, defined by hospitalization or death. Astegolimab every 2 weeks was associated with a 32% lower annualized severe exacerbation rate (RR, 0.68; 95% CI, 0.52–0.87; p=0.0028). However, because the prespecified statistical testing hierarchy was interrupted by a nonsignificant quality-of-life endpoint, this finding remains nominally significant rather than confirmatory.

Does Eosinophil Count Matter?
One of the analysis's more clinically relevant observations was the apparent benefit among patients with lower eosinophil counts. In those with fewer than 150 cells/μL, astegolimab every 2 weeks reduced exacerbation frequency by 18% (RR, 0.82; 95% CI, 0.70–0.97). Patients with fewer than 300 cells/μL experienced a 13% reduction (RR, 0.87; 95% CI, 0.77–0.99).

Numerical benefits also appeared in participants with higher eosinophil counts. However, overlapping confidence intervals and limited subgroup power prevent firm conclusions about whether eosinophil levels predict treatment response.

Patient-reported outcomes offered a more mixed picture. A clinically meaningful improvement of at least 4 points on the St George's Respiratory Questionnaire for COPD occurred in approximately 57% of patients receiving astegolimab every 2 weeks versus 49% receiving placebo. Yet mean questionnaire scores, respiratory symptom scores, and FEV1 changes did not differ significantly between groups.

Safety and the Path Toward Broader COPD Treatment

Astegolimab was generally well tolerated. Overall adverse event rates were 365 versus 408 events per 100 patient-years for every-2-week astegolimab and placebo, respectively, while serious adverse event rates were 38.9 versus 48.0. Infection rates were comparable, with no evident increase attributable to treatment.

The analysis benefits from its large, international population and prospectively planned pooling strategy. Nevertheless, the observed placebo exacerbation rate was lower than anticipated, reducing the statistical power of the individual trials. The modest primary effect, nonsignificant secondary outcomes, and exploratory subgroup findings also warrant caution.

Astegolimab's potential relevance lies in its activity across patients with frequent COPD exacerbations, including those without elevated eosinophil counts. These findings support IL-33/ST2 inhibition as a candidate strategy for broader exacerbation prevention, while leaving the magnitude of clinically meaningful benefit and the patients most likely to respond as important questions for further evaluation.

Reference:
Wedzicha JA, Agustí À, Brightling CE, et al. Astegolimab for chronic obstructive pulmonary disease with frequent exacerbations: pooled analysis of the ALIENTO and ARNASA trials. Am J Respir Crit Care Med. 2026;212(9):2050-2060. doi:10.1093/ajrccm/aamag226

Completing the pre-test is required to access this content.
Pre-Survey
Completing the pre-survey is required to access this content.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free